SSA
SPRY icon

Schonfeld Strategic Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$265K Buy
+33,032
New +$317K ﹤0.01% 1629
2024
Q3 		– Sell
-27,139
Closed -$231K – 2399
2024
Q2 		$231K Buy
+27,139
New +$241K ﹤0.01% 1768
2024
Q1 		– Sell
-16,500
Closed -$90.4K – 2384
2023
Q4 		$90.4K Buy
+16,500
New +$72.3K ﹤0.01% 1631
2022
Q4 		– Sell
-11,600
Closed -$62K – 2981
2022
Q3 		$62K Sell
11,600
-8,800
-43% -$43.4K ﹤0.01% 2613
2022
Q2 		$86K Sell
20,400
-8,100
-28% -$28.2K ﹤0.01% 2169
2022
Q1 		$100K Buy
+28,500
New +$124K ﹤0.01% 2232

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schonfeld Strategic Advisors's SPRY Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 33,032 shares worth $265K. The stake represents ﹤0.01% of the portfolio and ranks #1629 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in SPRY as recently as Q2 2024.

Schonfeld Strategic Advisors first reported a position in SPRY in Q1 2022 and has held it in 6 quarters since. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Schonfeld Strategic Advisors held 33,032 shares of ARS Pharmaceuticals worth $265K as of Q1 2026.
  • ARS Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1629 holding.
  • Schonfeld Strategic Advisors first reported a position in ARS Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.